Health Equity and Secukinumab for Severe Psoriasis in New Zealand
Between October 2018 and April 2021, the data suggest that the dispensing of secukinumab was inequitable. Those having severe psoriasis and being socio-economically disadvantaged or of Māori, Pacific and Asian compared to European ethnicity, were significantly less likely to have received secukinumab. Dermatologist workforce shortages in New Zealand are likely to compound the problem.
Authors
- Anna Luo (ORCID: https://orcid.org/0000-0001-7331-958X)
- Paul Jarrett (ORCID: https://orcid.org/0000-0002-4794-8830)
- Amanda MM Oakley (ORCID: https://orcid.org/0000-0002-9461-2790)
- Dug Yeo Han (ORCID: https://orcid.org/0009-0000-6222-2256)
Institutions
- University of Auckland (NZ)
- Middlemore Hospital (NZ)
- Waikato Hospital (NZ)
- Clinical Trials New Zealand (NZ)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1111/ajd.14539
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Waikato Medical Research Foundation